Statement of Principles concerning Wilson disease (Reasonable Hypothesis) (No. 47 of 2023)

The instrument rests on a limited set of statutory and medical concepts. The starting point is the medical definition of Wilson disease in s 7(2): a genetic disorder of copper metabolism characterised by impaired biliary copper excretion and toxic copper accumulation in organs such as liver and brain. That definition sets the clinical scope of the Statement. Relatedly, s 7(3) expands the concept of Wilson disease in relation to a person to include death from a terminal event or condition that the person’s Wilson disease contributed to. The Schedule 1 definition of terminal event makes clear that the term covers proximate or ultimate causes of death and explicitly lists pneumonia, respiratory failure, cardiac arrest, circulatory failure, and cessation of brain function as examples.

The statutory test that the Statement addresses is the “reasonable hypothesis” threshold used in the VEA/MRCA claims architecture. The RMA frames the Statement as identifying the factors that must exist before it can be said that a reasonable hypothesis has been raised connecting Wilson disease or death from Wilson disease with relevant service (s 9). The instrument therefore identifies evidentiary triggers rather than producing a conclusive causal finding.

Relevant service is a key legal concept located in Schedule 1. It is defined to include the particular categories under the VEA and MRCA: operational service, peacekeeping service, hazardous service, British nuclear test defence service (all under the VEA) and warlike or non‑warlike service under the MRCA (Schedule 1, definition of relevant service). The temporal and causal relationship to relevant service is prescribed in s 10(1) and s 10(2). Section 10(2) introduces a specific limitation: the s 9 factors apply only to material contribution to or aggravation of Wilson disease where the disease was suffered or contracted before or during, but did not arise out of, the person’s relevant service. That distinction creates separate treatment for disease that is pre‑existing or concurrent with service, compared to disease that arises out of service.

Section 8 records the RMA’s institutional view that “sound medical‑scientific evidence” exists supporting the possibility of a service relationship. That statement is presented as the RMA’s basis for determining the factors in s 9. The instrument itself does not reproduce the evidence, but it invokes a medical‑scientific basis as the reason these particular factors were selected.

Finally, s 11 deals with overlap between Statements of Principles. It instructs that where a factor in s 9 refers to an injury or disease already covered by another Statement determined under s 196B(2) of the VEA, then the factors in that other Statement apply according to their own terms as in force. This cross‑reference mechanism is a practical device to avoid inconsistent or duplicative criteria when comorbidity or secondary conditions are involved.

The instrument operates in the statutory claims environment established by the VEA and MRCA. The immediate operational players are the decision‑makers who apply section 120A of the VEA or section 338 of the MRCA to veterans and service personnel. Section 5 expressly limits application to claims governed by those provisions. The definitions in Schedule 1 show who counts as rendering relevant service for the instrument’s purposes. Relevant service includes operational, peacekeeping, hazardous and British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA (Schedule 1, relevant service). Therefore, claimants who served in any of those categories are within the instrument’s ambit.

Claimants whose Wilson disease was suffered or contracted before or during their relevant service are directly affected when they seek to establish material contribution to or aggravation of their condition by service, because s 10(2) expressly confines the s 9 factors to those circumstances. Conversely, the instrument does not extend the s 9 factors to cases where Wilson disease "arose out of" relevant service, because s 10(2) draws a boundary around material contribution or aggravation of pre‑existing or concurrent disease. Practitioners must therefore differentiate between disease that pre‑existed or was present during service and disease that first arose because of service when advising clients.

The Repatriation Medical Authority is the decision originator; it sets the medical criteria in this Statement (s 3 and s 8). The instrument will be used by adjudicative agencies and case officers in assessing entitlement issues under the VEA and MRCA, who must determine whether the facts raise the reasonable hypothesis threshold by reference to the s 9 factors and the service linkage requirements in s 10. Where the factors in s 9 refer to an injury or disease covered by another Statement, those other Statements become relevant to the claimant’s case (s 11).

Other affected parties include medical practitioners and experts who provide evidence on clinical worsening, pregnancy timing, and whether appropriate clinical management was available or obtained. The instrument’s wording makes those factual and clinical matters determinative of whether a “reasonable hypothesis” exists, and so the nature and quality of clinical records and expert opinion will materially affect the outcome.

Finally, because the instrument repeals the earlier Statement No. 33 of 2015 (s 4), claimants and decision‑makers dealing with cases spanning the repeal date must be aware of which Statement applies. The commencement clause fixes that transition point at 23 May 2023 (s 2), so disputes about which Statement governs claims around that date will turn on that timetable.

This Statement of Principles does not itself create new criminal offences or financial obligations in express terms; rather it defines the factual and medical criteria that decision‑makers must apply when assessing whether a reasonable hypothesis connects Wilson disease (or death from it) to relevant service. The operative duties fall on administrative decision‑makers within the statutory claims process under the VEA and MRCA, who must apply these factors when considering claims under the specified sections (s 5, s 9 and s 10).

The primary procedural duty for decision‑makers is to determine whether at least one of the factors in s 9 exists and whether that factor is related to the person’s relevant service in the manner required by s 10. In practical terms, the instrument requires that decision‑makers: (1) identify whether any of the enumerated factors is present (s 9); (2) establish that the factor was related to relevant service (s 10(1)); and (3) for material contribution or aggravation questions, confirm that the person’s Wilson disease was suffered or contracted before or during (but did not arise out of) relevant service (s 10(2)). Section 11 imposes an additional duty to consult and apply any other Statements of Principles where a s 9 factor refers to an injury or disease already covered by another Statement.

The instrument also sets an evidentiary benchmark for claimants’ advisers and medical experts. While the Statement does not prescribe specific types of evidence, it circumscribes the factual ground that must be established: pregnancy at the time of clinical worsening, or inability to obtain appropriate clinical management. Practitioners must therefore gather and present evidence directed to those matters if they seek to raise the reasonable hypothesis threshold under this Statement.

On the rights side, the instrument functions as a procedural and evidentiary aid to claimants seeking entitlements under the VEA and MRCA. By identifying the factors that raise a reasonable hypothesis, it signals the factual pathways by which a claimant may establish a service connection for Wilson disease or death from Wilson disease in the statutory claims process. The Statement does not itself grant benefits; rather it provides the RMA’s medical‑scientific criteria that decision‑makers use to determine whether the statutory threshold of a reasonable hypothesis is met for the purposes of the relevant claims provisions (s 5).

Because the Statement is made under s 196B(2) of the VEA, it has retrospective and prospective force as the RMA’s current statement of medical criteria for Wilson disease claims. The repeal of the 2015 Statement (s 4) transfers decision‑making to the new Statement from the commencement date (s 2), creating an administrative duty to apply the new criteria from 23 May 2023.

The instrument itself contains no penalty regime, sanctioning clauses, or enforcement procedures. Its text prescribes medical definitions and the factors that will be treated as raising a reasonable hypothesis connecting Wilson disease or death from it with relevant service (see s 7, s 9 and s 10), but it does not create offences, fines, or enforcement powers within the Statement itself. The authoritative function of the Statement is administrative and evidentiary: it provides decision‑makers with the RMA’s medical criteria to be applied in statutory claims under the VEA and MRCA.

Enforcement, to the extent it exists, is exercised through the claims process established by the VEA and MRCA. Section 5 states the Statement applies to claims to which s 120A of the VEA or s 338 of the MRCA applies. Those statutory provisions (which are outside this instrument) set out the mechanisms for the assessment, acceptance or rejection of claims and for any subsequent review or appeal. The Statement informs those determinations by fixing the factual thresholds decision‑makers must examine when considering whether a reasonable hypothesis exists.

Because there are no penalty clauses in the Statement, non‑compliance in the conventional regulatory sense does not arise from the instrument itself. Instead, the practical consequence of failing to establish the factors in s 9, or failing to demonstrate their relationship to relevant service under s 10, is likely administrative: a decision that the reasonable hypothesis threshold has not been met and therefore no entitlement under the relevant claim provision can be founded on Wilson disease or death from Wilson disease. Any remedial or review routes would be those provided in the VEA and MRCA and associated administrative review mechanisms.

Practitioners should therefore treat the Statement as evidence‑shaping guidance rather than as a source of criminal or civil sanctions. The instrument’s role is to define the RMA’s medical‑scientific position that must be considered by adjudicators; the effect of not satisfying the Statement’s criteria is administrative (adverse decision on entitlement), not penal, and enforcement of entitlements will proceed under the primary statutes referenced in s 5.

This Statement is a subordinate administrative instrument made under s 196B(2) of the VEA (s 3). Its legal effect is to inform and constrain the medical criteria used in claims adjudication under the VEA and MRCA. Section 5 expressly ties the application of the Statement to claims under s 120A of the VEA and s 338 of the MRCA. Those statutory provisions form the framework into which the RMA’s Statement is imported; the Statement does not amend or replace the substantive entitlement rules in the VEA or MRCA, but provides the medical factual tests relevant to establishing the service connection element within those statutes.

Schedule 1 embeds statutory cross‑references by defining VEA and MRCA and enumerating the categories of relevant service recognised under those Acts. Where a factor in s 9 refers to an injury or disease for which a separate Statement of Principles has been determined under s 196B(2) of the VEA, s 11 requires that the factors in that other Statement apply according to their terms. That cross‑application mechanism creates an operational interaction: a claim may require application of more than one Statement of Principles, and adjudicators must apply the terms of each Statement as in force.

The repeal clause (s 4) demonstrates temporal interaction between Statements: the new Statement replaces the older No. 33 of 2015 Statement from the commencement date (s 2). For claims that span the repeal date, the applicable Statement will generally be the one in force at the relevant decision time, subject to any transitional provisions in the primary Acts or administrative practice. The instrument itself does not specify transitional arrangements beyond the repeal; those will be governed by the VEA/MRCA decision practices and any broader administrative law considerations.

Because the Statement is limited to identifying factors that raise a reasonable hypothesis, substantive legal determinations under the VEA and MRCA,such as whether the claimant ultimately qualifies for a benefit, the nature and quantum of any entitlement, and the operation of other eligibility or exclusion provisions,remain matters for the primary Acts and the relevant decision‑makers who apply them. The Statement therefore interacts with other laws by supplying medical criteria and cross‑Statements to be used within the VEA/MRCA entitlement framework, without altering the underlying statutory rights and procedures established by those Acts.

The instrument records its own basic amendment and replacement history in discrete terms. It is formally dated 24 April 2023 and it commences on 23 May 2023 (s 2 and the front matter). It is identified as No. 47 of 2023 (title and front matter). Section 4 expressly repeals the earlier Statement of Principles concerning Wilson’s disease No. 33 of 2015 (Federal Register of Legislation No. F2014L01847) that was previously made under subsection 196B(2) of the VEA.

No other amendments to this Statement are recorded within the text. There are no in‑text amendment provisions or savings/transitional clauses other than the express repeal. The effect is that, from its commencement date, No. 47 of 2023 supersedes No. 33 of 2015. The instrument does not include retrospective amendments to earlier Statements beyond repeal, nor does it preserve the old Statement for any particular cases.

Practitioners should therefore treat the 2023 Statement as the operative RMA Statement for Wilson disease claims from 23 May 2023 onward. The instrument also anticipates that other Statements of Principles will remain in force and may be applied where s 9 references another injury or disease (s 11). Any future changes to the RMA’s view or to these criteria would require a further Statement made under s 196B(2) of the VEA and would likely appear on the Federal Register of Legislation in the usual manner.

The instrument gives no history of prior amendments to No. 33 of 2015 within its text; for a full amendment trail a practitioner would need to consult the Federal Register and the RMA’s records. What the instrument does make clear is the formal handover point and the repeal of the prior Statement on commencement.

The Statement itself contains no account of judicial or tribunal decisions and names no cases. It is an administrative instrument that sets medical criteria for decision‑makers rather than a judgment or regulation that arose from litigation. The text does not refer to any litigation history, decisions, or contested legal interpretations that informed the RMA’s determination. Section 8 describes the RMA’s view that there is sound medical‑scientific evidence connecting Wilson disease and death from Wilson disease to relevant service, but it does not cite legal authorities, litigation outcomes or specific studies within the instrument.

Because the instrument is silent on litigation, practitioners must look outside the Statement to find any case law dealing with Wilson disease claims under the VEA or MRCA, and any judicial treatment of the RMA’s Statements of Principles more generally. This instrument does not supply that material. The absence of litigation references in the text is itself relevant: the Statement presents the RMA’s medical criteria without anchoring them to particular tribunal or court decisions in the instrument.

If litigation arises challenging a decision that relied on this Statement, the usual review pathways under the VEA and MRCA and judicial review principles would apply. Any judicial findings about the application, sufficiency or interpretation of these factors would be authoritative for future cases, but such decisions, if they exist, are not included in this instrument and must be located from court or tribunal databases and the Federal Register.

1. Limited and tightly‑worded factors. The Statement requires at least one of two discrete factors to exist before a reasonable hypothesis is raised: pregnancy at the time of clinical worsening, or inability to obtain appropriate clinical management (s 9). Practitioners should not assume wider or alternative medical circumstances will, on their own, meet the reasonable hypothesis threshold under this Statement. The instrument does not list other factors.

2. Temporal and causal limitation. Section 10(2) narrows the application of the s 9 factors to material contribution to or aggravation of Wilson disease where the disease was suffered or contracted before or during, but did not arise out of, the person’s relevant service. This means the Statement is directed at pre‑existing or concurrent disease aggravated by service, not disease that originated as a direct consequence of service. Mischaracterising the timing of onset relative to service is a common procedural risk.

3. Undefined but decisive terms. The Statement uses key terms that it does not define in detail. For example, “clinical worsening” is not defined, and “inability to obtain appropriate clinical management” is not specified in terms of threshold, locality, or what counts as “appropriate”. These gaps create room for administrative interpretation and factual contest. Evidence requirements to prove inability to obtain appropriate management are not specified in the instrument, so claimants must anticipate that decision‑makers will require documentary proof and expert evidence.

4. Relationship to other Statements. Where a s 9 factor refers to another injury or disease covered by another Statement, s 11 requires that the other Statement’s factors apply. Practitioners must identify and apply any relevant secondary Statements for comorbid conditions. Failure to do so risks an incomplete evidentiary presentation.

5. Death from Wilson disease and terminal events. The definition of death from Wilson disease includes death from a terminal event or condition that was contributed to by Wilson disease (s 7(3)). Schedule 1 defines “terminal event” broadly as the proximate or ultimate cause and lists examples. The use of “includes” in the Schedule suggests the list is illustrative rather than exhaustive. Establishing that a listed terminal event was contributed to by Wilson disease will require causation evidence linking the clinical course to copper accumulation and the disease’s effects.

6. Repeal timing. The new Statement repeals the 2015 Statement (s 4) and commences on a specific date (s 2). Claims spanning the repeal date may raise questions about which criteria should apply. The instrument does not set out transitional rules other than the repeal; practitioners must therefore be careful when advising on claims that involve events or decisions around 23 May 2023.

7. No procedural detail on evidence standards. The Statement sets the factors but does not give procedural guidance on evidentiary standards, burden of proof or how to prove inability to obtain management. That silence transfers practical evidence questions to the statutory adjudicators and to relevant case law and administrative practice outside the instrument.

8. Possible overlap with other causes. Because Wilson disease is a systemic condition that can affect liver and brain, factual causation involving terminal events may intersect with other medical conditions or injuries. Where other Statements of Principles exist for related conditions, s 11’s cross‑application may complicate the claim and increase the evidentiary burden.

9. Administrative discretion risk. The lack of precise definitions for core terms means different adjudicators could reach different conclusions in otherwise similar factual patterns. This increases the risk of inconsistent outcomes and may require focused expert evidence to anchor interpretations.

10. Narrow pathway for raising the reasonable hypothesis. The Statement provides only two routes to raise the reasonable hypothesis. If a claimant’s factual profile does not fit within pregnancy‑related worsening or inability to obtain appropriate management, the Statement as written will not support a reasonable hypothesis under RMA criteria. Practitioners must therefore map client facts carefully against s 9 and s 10 before relying on this Statement.

1. Identify the relevant statutory pathway. Confirm that the claim is one to which s 120A of the VEA or s 338 of the MRCA applies (s 5). The Statement applies only to claims under those provisions. If the claim uses a different statutory basis, this Statement will not be the determinative RMA criteria.

2. Establish Wilson disease diagnosis and timing. Gather clinical records that establish a diagnosis of Wilson disease and document when the disease was suffered or contracted relative to the period of relevant service. Section 10(2) requires that the RMA factors apply only where the disease was suffered or contracted before or during, but did not arise out of, relevant service. Records should therefore show onset dates, diagnostic tests, and any pre‑service or in‑service symptoms.

3. Match facts to the s 9 factors. The claimant must establish at least one of the enumerated factors in s 9:

   • For pregnancy: demonstrate that the person was pregnant at the time of clinical worsening. Clinical notes, obstetric records, hospital charts and contemporaneous GP or specialist notes should be obtained to record both pregnancy status and the timing and nature of clinical deterioration.
   • For inability to obtain appropriate clinical management: assemble contemporaneous evidence of attempts to obtain care during the relevant period, and documentation that appropriate management was unavailable, inaccessible, or was not provided. This may include referral records, appointment logs, correspondence with health services, operational medical records if in theatre or deployed, and statements about the local availability of specialists or treatments.

4. Link the factor to relevant service. Under s 10(1) the existence of any factor in s 9 must be related to the person’s relevant service. Demonstrate how the pregnancy‑related worsening or lack of access to appropriate management occurred in the context of the defined relevant service period or conditions. Use service records, deployment logs, medical evacuation records, and contemporaneous unit or base medical service documentation to show the relationship.

5. Address comorbidity and cross‑Statements. If the factor refers to an injury or disease covered by another Statement of Principles, identify that Statement and ensure the evidence addresses its factors as required by s 11. Practically, this means obtaining and presenting the evidence that the other Statement requires, in addition to the s 9 evidence.

6. Prepare expert medical evidence. Because the Statement turns on clinical worsening, availability of appropriate management and contribution to terminal events, provide expert opinion that addresses those questions expressly. Experts should tie clinical facts to the RMA’s definitions: explain whether the clinical deterioration qualifies as “clinical worsening”, whether the care sought met the standard of “appropriate clinical management”, and whether Wilson disease contributed to a terminal event listed or described in Schedule 1.

7. Anticipate definitional disputes. The instrument leaves key terms undefined. Expect adjudicators to test what counts as “appropriate” management and what constitutes “inability to obtain” it. Provide contextual and local health system evidence where relevant, such as standard of care at the time and location, referral pathways, and whether alternatives were available.

8. Document contemporaneous facts. File copies of all contemporaneous records: deployment rosters, medical clinic notes, evacuation or transfer records, specialist appointment logs, and correspondence showing attempts to obtain care. For pregnancy cases, secure obstetric and antenatal records recording dates and any complications or exacerbations. For death‑related claims, include cause of death documentation and linkage to Wilson disease as a contributing factor.

9. Address timing around repeal and commencement. For cases involving events that straddle the 23 May 2023 commencement date, identify which Statement was in force at the relevant decision point and prepare argument and evidence accordingly. The instrument repeals the 2015 Statement (s 4), so practitioners must be clear which criteria apply to their client’s case.

10. Prepare for cross‑examination of chain of causation. Where the claim hinges on contribution to a terminal event, be ready to show how copper accumulation or the disease process materially contributed to the listed proximate or ultimate cause of death. Provide pathology and clinical notes that support the causal pathway, and an expert who can explain the disease’s mechanism in terms that relate to the Schedule 1 definition of terminal event.

11. Use a checklist approach. Practically, adopt a compliance checklist that maps each element of s 9 and s 10 to available evidence, identifies any other Statements engaged under s 11, and sets out expert opinion required to link facts to the RMA’s definitions. This reduces the risk of overlooking the instrument’s narrow pathways.

12. Maintain records of administrative decisions. Because the Statement functions as administrative guidance to decision‑makers, collect and preserve decision letters and reasons so that, if an adverse outcome follows, there is a clear record for internal review and any external merits or judicial review processes available under the VEA/MRCA framework.

Following these steps will align a claim file to the specific, narrow criteria set out in the RMA’s Statement and will focus evidence on the two routes the instrument identifies for raising a reasonable hypothesis that Wilson disease or death from Wilson disease is related to relevant service (s 9), and on the temporal and causal limits in s 10.